Veracyte, Inc. announced that Kevin Haas, Ph.D., 40, has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company?s global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company?s end-to-end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. As Veracyte?s pipeline expands into whole-genome minimal residual disease (MRD) and other multi-omics applications, product development requires integrated capabilities across assays, software, AI, and next-generation informatics to support solutions from diagnosis to disease management.
In this role, Dr. Haas will lead these efforts to deliver high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products. He will bring these capabilities together to accelerate innovation and support the company?s global portfolio. Dr. Haas has more than 15 years of life sciences industry experience, leading teams across technology, research, and development.
Most recently, he served as Chief Technology Officer at Myriad Genetics, where he led the development of the company?s precision medicine platform and digital health strategy. Prior to that, Dr. Haas was Senior Vice President of Engineering at Myriad and Vice President of Bioinformatics at Myriad Women's Health. Before joining Myriad, he held leadership roles in lab engineering and bioinformatics at Counsyl.
Dr. Haas has expertise in creating automated lab technology and AI systems to derive insights from genomics data, and in launching scalable molecular assays. He received a B.S. from University of Wisconsin-Madison and a Ph.D. in chemical engineering from University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics.
